TLDR Baricitinib reduces inflammation and improves cell health in premature aging cells.
The study demonstrated that inhibiting the JAK-STAT signaling pathway with Baricitinib reduced inflammation and improved cellular homeostasis in Hutchinson-Gilford Progeria Syndrome (HGPS) cells. Baricitinib treatment decreased progerin levels, improved nuclear morphology, and reduced the expression of proinflammatory factors such as IL6, IL8, IL18, and CCL2. Additionally, it delayed senescence and enhanced mitochondrial function in both normal and HGPS cells. These findings suggested that Baricitinib could be a valuable therapeutic strategy for managing HGPS and other age-related conditions involving chronic inflammation and cellular dysfunction.
15 citations,
January 2016 in “Biological & Pharmaceutical Bulletin” Bee venom helps hair grow and may work better than some common treatments.
38 citations,
February 2009 in “Journal of The European Academy of Dermatology and Venereology” Severe vertex pattern hair loss may indicate a higher risk for artery plaque buildup.
4 citations,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
November 2023 in “Frontiers in cell and developmental biology” Hair aging is caused by stress, hormones, inflammation, and DNA damage affecting hair growth and color.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
489 citations,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
